AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device …
Aug 1, 2022 · Anonymous board for AstraZeneca.
AstraZeneca reports positive data from Phase III trial of efzimfotase ...
Apr 1, 2026 · AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic bone disorder. The global programme …
AstraZeneca says it will build cell therapy base, innovation centre in ...
Mar 19, 2026 · AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and innovation centre in Shanghai, aiming to become the first global drugmaker with end-to-end cell …
Abivax denies French media report of AstraZeneca takeover | Cafepharma
Mar 16, 2026 · Abivax shares soared on Thursday after a French media report that AstraZeneca was in talks to acquire it. But a company spokesperson denied the report to CNBC. Abivax has been the …
AstraZeneca’s novel COPD drug secures double win in Phase III
Mar 27, 2026 · AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic obstructive pulmonary disease (COPD), which analysts say could position the drug to …
July 24 2025 - AstraZeneca drug acquired in Alexion deal succeeds in ...
Jul 24, 2025 · AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trialAstraZeneca boardPharma giant Roche sees income soar in first halfRoche boardNovartis to pay …
Merck, AstraZeneca report positive data for Koselugo in adults
Nov 12, 2024 · AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) reported positive topline results from a Phase 3 study of their drug Koselugo in the treatment of neurofibromatosis type 1, or NF1.
AstraZeneca’s Strensiq successor misses phase 3 rare disease goal ...
Mar 31, 2026 · A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the company’s ability to expand beyond the children served by its …
AstraZeneca | Cafepharma
3 days ago · AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic bone disorder. The global programme …
Sanofi, AstraZeneca and Sobi simplify Beyfortus agreements ahead of …
Apr 12, 2023 · The modification of an existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of RSV antibody Beyfortus (nirsevimab) and 'enhanced agility' in the US market.